BBS-Bioactive Bone Substitutes Oyj (BONEH.HE)
| Previous close | 0.4720 |
| Open | 0.4740 |
| Bid | 0.4620 x N/A |
| Ask | 0.4690 x N/A |
| Day's range | 0.4620 - 0.4740 |
| 52-week range | 0.3613 - 0.9196 |
| Volume | |
| Avg. volume | 32,295 |
| Market cap | 8.617M |
| Beta (5Y monthly) | -0.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.50 |
GlobeNewswireChanges in BBS-Bioactive Bone Substitutes Plc’s Management Team
BBS-Bioactive Bone Substitutes Plc, Company announcement, 6 March 2024 at 11:15 a.m. Changes in the BBS-Bioactive Bone Substitutes Plc’s Management Team Oy Jamerco Ltd. has terminated its service contract with BBS-Bioactive Bone Substitutes Ltd (“BBS”). As a result, Jari Kortesluoma’s position as the CFO and member of the management team will end. Kortesluoma will fulfill the responsibilities of CFO throughout the two-month notice period. BBS is currently in the process of searching for a new in
- GlobeNewswire
BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023: Preparations for commercial phase initiated (unaudited)
BBS-Bioactive Bone Substitutes Plc, Financial Statements Bulletin 2023, 26 February 2024 at 5.45 p.m. (EET) This is a summary of BBS-Bioactive Bone Substitutes Plc’s Financial Statements Bulletin for January–December 2023. The entire report is attached to this Company Announcement as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc’s website at https://www.bbs-artebone.fi/. Preparations for commercial phase initiated JULY-DECEMBER HIGHLIGHTS In the second half of 20
Globe NewswireInside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position
BBS-Bioactive Bone Substitutes Plc, Company announcement, inside information, 21 February 2024 at 10:30 am EET Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position BBS-Bioactive Bone Substitutes Plc's (“BBS”, “the Company”) has signed the drawdown of the advance of EUR 500.000, pursuant to the terms and conditions of the Financing Agreement between BBS and RiverFort Global Opportunities Pcc Li
